Author:
Kanis John A.,McCloskey Eugene V.,Jonsson Bengt,Cooper Alun,Ström Oskar,Borgström Fredrik
Publisher
Springer Science and Business Media LLC
Subject
Orthopedics and Sports Medicine
Reference127 articles.
1. Kanis JA, Johnell O (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:229–238
2. Dolan P, Torgerson DJ (2000) The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 11:551–552
3. Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359:2018–2026
4. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster J-Y, Borgstrom F, Rizzoli R, on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428
5. National Institute for Clinical Excellence (2005) Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. NICE, London
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献